TOKYO, Jan 18, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from […]

SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration […]

HONG KONG, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that interim safety and efficacy data of dose expansion cohort from the phase I/II study of TST001 […]

LAUSANNE, Switzerland, Sep 6, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety […]

Seoul, Korea,June8, 2022- (SEAPRWire) – Lemon Healthcare, a customized service platform, is using blockchain technology to improve the smart healthcare ecosystem for patients. The company is on a mission to create an efficient and convenient platform that allows patients to access medical records, manage appointments, and communicate with medical professionals. Additionally, […]

SHANGHAI, CHINA, Jun 7, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. A post-hoc analysis that involved […]

TOKYO, May 27, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from […]

HONG KONG, Mar 14, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased […]

TOKYO, Jan 31, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA (generic name: pembrolizumab) has been approved in Taiwan for […]

Strasbourg, France & Tokyo, Japan, Nov 23, 2021 – (JCN Newswire via SEAPRWire.com) – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, today announce positive preliminary […]

MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 – (ACN Newswire via SEAPRWire.com) – Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and […]

NEW JERSEY, the U.S. and HANGZHOU, China, Sep 8, 2021 – (ACN Newswire via SEAPRWire.com) – Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple […]

TOKYO, Aug 2, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as “a monotherapy for partial-onset seizures” and “an adjunctive treatment / a monotherapy for pediatric indication for […]